Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Seretide withdrawal in COPD using non-invasive biomarkers
2004-003833-15Phase 4Completed
- Sponsor
- Manchester University NHS Foundation Trust
- Start
- Feb 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of salmeterol + fluticasone in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by Manchester University NHS Foundation Trust. Primary endpoint: Induced sputum inflammatory cell counts. Started Feb 2005; status: completed.
02
Drugs
salmeterol + fluticasone
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2004-003833-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-003833-15.